Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).

immunostimulants
bone marrow procedure
treatment regimen
primary cancer
neuropathy
  • 0 views
  • 28 Jul, 2022
  • 6 locations
Apatinib in the Treatment of Recurrent Atypical/Malignant Meningioma in Adults

Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed atypical/malignant meningioma.

Accepts healthy volunteers
  • 0 views
  • 24 Mar, 2022
  • 1 location
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Primary Objective: To determine the response rate (RR) of metastatic or locally advanced pheochromocytoma/paraganglioma to axitinib administered daily. Secondary Objectives: Determine the progression-free survival. In an exploratory manner examine the extent of activation of the VEGFR pathway in pheochromocytoma/paraganglioma using a semi-quantitative immunohistochemistry assay and examine the relationship with response …

neutrophil count
platelet count
metastatic disease
iobenguane
amylase
  • 1 views
  • 07 Feb, 2022
  • 1 location
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

a monocenter, open label, single arm, phase II study of the combination of axitinib with avelumab as neoadjuvant therapy in patients with intermediate to high-risk non-metastatic RCC.

renal function tests
serum pregnancy test
axitinib
renal function
carcinoma
  • 11 views
  • 03 Mar, 2022
  • 1 location
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases (CABRAMET)

This is a multicenter, open-label, exploratory, single-arm, prospective phase II study to assess the efficacy and safety profile of cabozantinib in patients with brain metastases from metastatic renal cell carcinoma (mRCC).

neutrophil count
metastasis
cabozantinib
brain metastases
  • 2 views
  • 21 Feb, 2022
  • 4 locations
A Clinico-biological Database in Cachexia in Patients With Colon Cancer (BCB Cachexie)

Creation of a prospective clinico-biological database dedicated to cachexia and undernutrition in order to carry out future research projects, to improve our knowledge of colon cancer and cachexia and to optimize the therapeutic management of patients

  • 0 views
  • 09 Apr, 2022
  • 1 location
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D). Primary Objective Dose Expansion: To evaluate the anticancer activity of surufatinib in patients with advanced Biliary Tract Cancer …

solid tumor
primary cancer
sarcoma
everolimus
sunitinib
  • 83 views
  • 13 May, 2022
  • 12 locations
Endoscopic Ultrasound Radiofrequency Ablation for GISTs

Nowadays, for the selection of the treatment for gastrointestinal stromal tumors (GISTs), tumor size, prognosis, resectability and stage should be considered. Due to mutations in KIT and platelet-derived growth factor alpha (PDGFRA) in 90% of patients with this mesenchymal tumor, many tyrosine kinase inhibitors are used. On the other hand, …

  • 0 views
  • 28 Jul, 2022
Selective Treatment According to Molecular Subtype of Prostate Cancer (STAMP)

This is an open-label study that includes three substudies of random distribution. First, a sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical technique to determine several markers. Depending on the expression of these markers, the patients will be characterize as group 1 (Luminal …

testosterone
serum testosterone
  • 1 views
  • 14 Feb, 2022
  • 1 location
Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST) (METAGIST)

well as mutational status. Advanced and relapsing forms are currently treated with oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR such as Imatinib, Sunitinib and Regorafenib. Over two decades

  • 0 views
  • 08 Feb, 2022
  • 1 location